Clinical Research on the efficacy evaluation and the biomarker of nivolumab to an advance malignant melanoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Jan 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms CREATIVE; CSPOR
- 11 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 28 Aug 2015 Planned initiation date changed from 1 Jan 2015 to 1 Sep 2015 as per University Hospital Medical Information Network - Japan.
- 27 Aug 2015 Status changed from not yet recruiting to recruiting as per University Hospital Medical Information Network - Japan.